Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy.
- DOI
- 10.1016/j.scib.2026.08.080
- Published
- 2026 Aug 31
- Container
- Science bulletin
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.scib.2026.08.080,
title = {Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy.},
author = {Zhu L and Ma YJ and Kang JK and Che XH and Zhao DK and Cai YY and Yu YR and Shen S and Wang J},
year = {2026},
journal = {Science bulletin},
doi = {10.1016/j.scib.2026.08.080},
url = {https://doi.org/10.1016/j.scib.2026.08.080}
}RIS
TY - JOUR TI - Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy. AU - Zhu L AU - Ma YJ AU - Kang JK AU - Che XH AU - Zhao DK AU - Cai YY AU - Yu YR AU - Shen S AU - Wang J PY - 2026 JO - Science bulletin DO - 10.1016/j.scib.2026.08.080 UR - https://doi.org/10.1016/j.scib.2026.08.080 ER -
APA
L, Z., YJ, M., JK, K., XH, C., DK, Z., YY, C., YR, Y., S, S., & J, W. (2026). Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy.. Science bulletin. https://doi.org/10.1016/j.scib.2026.08.080
Source records
- pubmed · retrieved 2026-09-25T04:45:04.614Z
- europe-pmc · retrieved 2026-09-25T04:45:04.691Z